Embla Medical hf: Interim Report Q2 2024
· Delivering our highest ever quarterly sales amounting to USD 217 million · Organic growth of 6% for Q2 driven strong performance in Prosthetics & Neuro Orthotics and Patient Care · EBITDA was USD 47 million and EBITDA margin was 22% for Q2 · Medicare in the US has finalized a proposal that grants active K2 patients access to prosthetic knees · New exciting innovation launched in bionics with NAVii[®] by Össur and Icon[®] by College ParkAnnouncement no. 11/2024 Interim report Q2 2024 23 July 2024 Sveinn Sölvason, President and CEO, comments: “We delivered our